Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$25.15 USD
+0.49 (1.99%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $25.11 -0.04 (-0.16%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth C Momentum C VGM
Income Statements
Fiscal Year end for Protagonist Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 60 | 27 | 27 | 29 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 60 | 27 | 27 | 29 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 154 | 158 | 153 | 93 | 81 |
Income After Depreciation & Amortization | -94 | -131 | -126 | -65 | -81 |
Non-Operating Income | 15 | 4 | 0 | 0 | 3 |
Interest Expense | 0 | 0 | 0 | 1 | 0 |
Pretax Income | -79 | -127 | -126 | -65 | -78 |
Income Taxes | 0 | 0 | 0 | 1 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -79 | -127 | -126 | -66 | -77 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -79 | -127 | -126 | -66 | -77 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -95 | -129 | -121 | -62 | -79 |
Depreciation & Amortization (Cash Flow) | -1 | 3 | 5 | 3 | 2 |
Income After Depreciation & Amortization | -94 | -131 | -126 | -65 | -81 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 56.76 | 49.04 | 46.32 | 34.40 | 25.89 |
Diluted EPS Before Non-Recurring Items | -1.39 | -2.60 | -2.71 | -1.92 | -2.98 |
Diluted Net EPS (GAAP) | -1.39 | -2.60 | -2.71 | -1.92 | -2.98 |
Fiscal Year end for Protagonist Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 60.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 60.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 36.95 | 38.32 | 42.35 | 36.03 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 23.05 | -38.32 | -42.35 | -36.03 |
Non-Operating Income | NA | 4.29 | 4.22 | 3.89 | 2.30 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | 27.34 | -34.11 | -38.46 | -33.73 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 27.34 | -34.11 | -38.46 | -33.73 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 27.34 | -34.11 | -38.46 | -33.73 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 61.80 | 59.18 | 56.78 | 50.57 |
Diluted EPS Before Non-Recurring Items | NA | 0.44 | -0.58 | -0.68 | -0.67 |
Diluted Net EPS (GAAP) | NA | 0.54 | -0.58 | -0.68 | -0.67 |